BioNeutral Group Hosts Discussions with Four of the World's Largest Health Care Companies

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced discussions with four of the world’s largest health care companies. The discussions included both scientific and business representatives all interested in BioNeutral's game changing technology - "Sporicidal performance on surfaces and skin.” Game changing technology is an infrequent occurrence. However, it is easy to identify and differentiate from the run of the mill or obsolete technology and thus generates intense interest. BioNeutral is in a unique position in that it has not solicited contacts with major players in the antimicrobial and health care arena; instead these well known companies have been contacting BioNeutral to develop partnering relationships.

Any antimicrobial which is not sporicidal may be a carrier for the dangerous and difficult to kill organisms which may then be transported from person to person (this includes all known alcohol, silver or quat based formulations). For example, Clostridium Difficile spores are associated with hospital acquired infections which results in diverted heath care provider’s efforts, millions of dollars in extra expenses and hundreds of thousands of unnecessary deaths annually in the US alone. The best high powered currently used hospital disinfectants based upon quaternary ammonium compounds, silver based disinfectants or alcohol washes are totally ineffective at eradicating Clostridium Difficile (C-diff) spores, resulting in a serious unmet need in the health care arena. BioNeutral’s Ygiene™ is the clear solution for this serious problem.

Dr. Andy Kielbania, Chief Scientist at BioNeutral Group stated, "Results of in-house testing conducted this past week demonstrated a 30 second kill time for the most difficult to kill spores with a mild formulation that is gentle to skin, surfaces and fabric. These are the best results we have produced thus far.”

“When these results are confirmed by independent testing,” said one of the health care executives, “It represents a game changer which will determine control of a worldwide antimicrobial health care market.”

BioNeutral Group Inc. CEO, Stephen J. Browand, stated, "If game changing technology were presently out there, we would not be inundated with calls from the major players in the healthcare field. Killing low level microorganisms with old, me too technology (alcohol, silver, quats or bleach) has been available for quite some time. Rapidily eliminating dangerous spores such as Clostridium Difficile (C-diff) with our new mild Ygiene™ formulation which can be exposed to skin is considered the holy grail of antimicrobial performance. Independent lab testing confirming last week’s R&D breakthrough should take approximately three weeks".

BioNeutral Group Inc. has confirmed independent test results which indisputably show the Company’s Ygiene™ formulations outperform virtually all antimicrobials available when it comes to difficult to kill, dangerous organisms including black mold. Dissimilar to silver, bleach and quat based older technology; BioNeutral’s Ygiene™ is non corrosive, non-staining, non flammable and completely sporicidal.

About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and Chemo Neutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. More information about the Company may be found at www.bioneutralgroup.com

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.